Even in glioblastomas where EZH2 is overexpressed, prolonged depletion of Ezh2 results in a switch in cell fate that promotes tumor progression [12], suggesting that a careful regimen for treating tumors with EZH2 inhibitors should be considered to maximize the benefits. The gene discussed is EZH2; the disease is neoplasm.